Allogene Therapeutics, Inc. Share Price
NASDAQ: ALLO | Small CapAllogene Therapeutics, Inc. Stock Performance
Open $1.99 | Prev. Close $2.00 | Circuit Range N/A |
Day Range $1.99 - $2.10 | Year Range $0.99 - $4.45 | Volume 2,57,836 |
Average Traded $2.06 |
Allogene Therapeutics, Inc. Share Price Today
As of 11 August 2026, Allogene Therapeutics, Inc.'s share price is $2.10. The stock opened at $1.99, compared to its previous close of $2.00. During today's trading session, Allogene Therapeutics, Inc.'s share price traded between $1.99 and $2.10, with an average price of $2.04. Over the past 52 weeks, the stock has recorded a high of $4.45 and a low of $0.99. In terms of performance, Allogene Therapeutics, Inc.'s share price has declined by 24.91% over the last six months and is up 83.77% on a year-on-year basis.
Allogene Therapeutics, Inc. Share Price Chart
Allogene Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $462.20M | PE Ratio (TTM) -2.41 | Dividend Yield N/A |
EPS (TTM) $-0.87 | Revenue (TTM) N/A | Return On Equity (TTM) -65.25% |
Profit Margin N/A | Debt to Equity 0.11 | Quarterly Earnings Growth YoY 37.55% |
Allogene Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Allogene Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.87 | $2.00 | +7.22% |
Jul 2026 | $2.05 | $1.87 | -9.88% |
Jun 2026 | $2.18 | $2.08 | -5.03% |
May 2026 | $2.09 | $2.19 | +2.82% |
Apr 2026 | $2.50 | $2.13 | -12.91% |
Mar 2026 | $2.67 | $2.44 | -12.54% |
Feb 2026 | $1.80 | $2.79 | +51.63% |
Jan 2026 | $1.35 | $1.84 | +34.80% |
Dec 2025 | $1.45 | $1.36 | -5.86% |
Nov 2025 | $1.26 | $1.45 | +17.41% |
Oct 2025 | $1.25 | $1.24 | -0.40% |
Sep 2025 | $1.15 | $1.24 | +8.77% |
ALLO Share Price FAQs
What is Allogene Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Allogene Therapeutics, Inc. stock?
What is ALLO's market capitalisation today?
What is ALLO's net income for the last quarter?
What is the 5 year returns of ALLO?
What is the high & low stock price of ALLO today?
Can I buy ALLO shares in India?